Medication Guide for Cabozantinib and PD-1 Combination Therapy

Cabozantinib (Cabozantinib) can effectively inhibit multiple targets such as MET, VEGFR1/2/3, ROS1, RET, AXL, NTRK, and KIT. This drug has been recognized as having significant efficacy in the treatment of medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. With the deepening of research, the combination of cabozantinib and other drugs, especially the combination with immunotherapy, is showing broader therapeutic prospects.

PD-1, as a key protein in the immune system, inhibits T cell activity by binding to PD-L1 or PD-L2, thereby regulating immune responses. When cabozantinib is combined with a PD-1 inhibitor, their common goal is to break the immune evasion strategy of tumor cells and enhance the effectiveness of the immune system in attacking tumors. Especially in the study of hepatocellular carcinoma, experimental data in mouse models have confirmed that this combination can significantly improve the objective response rate of treatment compared with cabozantinib alone.

When cabozantinib andPD-1 inhibitors are used together, the dosage of the drug is by no means static. It must be precisely tailored based on the patient's weight, liver and kidney function, severity of the condition, and the individualized treatment plan prescribed by the doctor. Regarding the method of taking Cabozantinib, it is usually recommended that patients take it orally on an empty stomach, that is, avoid eating 2 hours before taking the drug and 1 hour after taking the drug, and swallow the pill whole and avoid crushing.

During treatment, close monitoring of the patient is essential. This includes observing the side effects and adverse reactions of drugs so that treatment plans can be adjusted in a timely manner to ensure the safety and health of patients. Through this comprehensive treatment approach, we hope to open up new and more effective treatments for cancer patients.